For end stage renal disease (ESRD). ANDA 211038, held by Cohance Lifesciences. Calcium Acetate.
As of Nov 16, 2026, ANDA 211038 (Calcium Acetate), held by Cohance Lifesciences, was first approved by FDA on Feb 21, 2020, with 2 approved supplements and 0 published complete response letters.
Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 21, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Calcium Acetate667MG · capsule;oral | Calcium Acetate | Rx |
| Nov 17, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 17, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 21, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters